Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
Authors
da Silva, I. P.Ahmed, T.
Reijers, I. L. M.
Warner, A. B.
Patrinely, J. R.
Serra-Bellver, Patricio
Allayous, C.
Mangana, J.
Zimmer, L.
Trojaniello, C.
Klein, O.
Gerard, C. L.
Michielin, O.
Haydon, A.
Ascierto, P. A.
Carlino, M. S.
Lebbe, C.
Lorigan, Paul C
Johnson, D. B.
Sandhu, S.
Lo, S. N.
Menzies, A. M
Long, G. V.
Affiliation
Melanoma Institute Australia, University of Sydney, Sydney, NSW, AustraliaIssue Date
2021
Metadata
Show full item recordAbstract
NoneCitation
da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, et al. Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors’ reply. The Lancet Oncology. 2021 Aug;22(8):e343–4.Journal
Lancet OncologyDOI
10.1016/s1470-2045(21)00419-8PubMed ID
34339647Additional Links
https://dx.doi.org/10.1016/s1470-2045(21)00419-8Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s1470-2045(21)00419-8
Scopus Count
Collections
Related articles
- Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma.
- Authors: Li M
- Issue date: 2021 Aug
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
- Authors: Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV
- Issue date: 2021 Jun
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
- Authors: Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD
- Issue date: 2018 Nov
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
- Authors: Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D, Dermatologic Cooperative Oncology Group.
- Issue date: 2020 May 16
- Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
- Authors: Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T
- Issue date: 2020 Sep 1